{"id":4773,"date":"2025-01-23T06:21:22","date_gmt":"2025-01-22T20:21:22","guid":{"rendered":"\/eu-uk\/?p=4773"},"modified":"2025-01-23T06:21:22","modified_gmt":"2025-01-22T20:21:22","slug":"stockhead-orthocell-soars-14-after-crushing-early-sales-growth-for-remplir","status":"publish","type":"post","link":"\/eu-uk\/blog\/2025\/01\/23\/stockhead-orthocell-soars-14-after-crushing-early-sales-growth-for-remplir\/","title":{"rendered":"Stockhead | Orthocell soars 14% after crushing early sales growth for Remplir"},"content":{"rendered":"

Orthocell’s plans to broaden its commercial footprint in existing and new markets drove the company’s share price up 13.8% this week, according to a special report in Stockhead.<\/p>\n

The rise followed news of Orthocell plans to accelerate efforts to enter several key markets across CY25 including Thailand, Canada, the UK, Brazil and European Union, building on a third quarter of record revenue.<\/p>\n

Here’s an excerpt:
\n“Perth-headquartered Orthocell was a hero of the ASX healthcare sector in 2024. The company is up more than 265% in the past year and ~20% over the past month. Orthocell sits among the top five performing ASX healthcare stocks of the past year.”<\/p>\n

Click to read the full article.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Orthocell’s plans to broaden its commercial footprint in existing and new markets drove the company’s share price up 13.8% this week, according to a special report in Stockhead.<\/p>\n","protected":false},"author":2,"featured_media":4751,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[3],"tags":[],"class_list":["post-4773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-media"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t